CordenPharma ups Swiss API development services

By Staff Reporter

- Last updated on GMT

GettyImages/Golden_Brown
GettyImages/Golden_Brown

Related tags Capital accumulation Investment

CordenPharma has invested in its Swiss API development services a week after buying a manufacturing plant from Pfizer.

The contract development and manufacturing organisation (CDMO) said it is investing €3.7m ($4.4m) into its site in Liestal, Switzerland to increase its small molecule development services and refurbish its purification capabilities.

Around €2m of the investment will be used to add automation equipment at the plant “to facilitate development services and an extensive upgrading and expansion of analytical equipment,”​ the firm said. But despite the automation tech, the firm expects an increase in the overall number of development staff.

The rest of the investment will be used to build a mini-plant and refurbish current purification capabilities at the site, to meet growing market demands in the g to kg’s range and at a scale of 1-70 liters, the firm said.

“The introduction of this new mini-plant will enable us to run small-scale batches for our customers, while at the same time demonstrating the routes readiness for further scale-up and addressing their material requirements for early-phase clinical stages,”​ Juerg Burger, managing director of CordenPharma Switzerland, said in a press release.

The expansion comes a week after the CDMO announced it was buying a highly potent active pharmaceutical ingredient (HPAPI) plant from Pfizer​ in Boulder, Colorado.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Related suppliers

Follow us

Products

View more

Webinars